This bill amends and reenacts specific sections of Louisiana's controlled substances law, particularly R.S. 40:964, which outlines the composition of various schedules of controlled substances. The bill introduces new substances to Schedule I and Schedule IV, including several fentanyl analogs, hallucinogenic substances, and depressants. Notably, it adds five new entries to Schedule I (2',5'-dimethoxyfentanyl, alpha'-methyl butyryl fentanyl, para-methoxyfuranyl fentanyl, para-methylcyclopropyl fentanyl, and 2-Methyl AP-237) and four new hallucinogenic substances (4-chloro-2,5-dimethoxyamphetamine, 4-iodo-2,5-dimethoxyamphetamine, 5-methoxy-alpha-methyltryptamine, and 5-methoxy-N,N-diethyltryptamine). Additionally, it includes three new depressants (Diclazepam, Flubromazolam, and Bromazolam) and one new entry in Schedule IV (Zuranolone).

The bill also makes several deletions and modifications to existing language, such as changing "arylalkylhalide" to "alkylarylhalide" in the descriptions of certain synthetic cannabinoids. Furthermore, it authorizes the Louisiana State Law Institute to renumber the new entries to ensure they are organized alphabetically. Overall, this legislation aims to update the state's controlled substances schedules to reflect current drug trends and enhance public health and safety.

Statutes affected:
HB204 Original: 40:964(S
HB204 Engrossed: 40:964(S
HB204 Enrolled: 40:964(S
HB204 Act 110: 40:964(S